The DOI matches its Crossref record.
Identification of Novel Inhibitors of the SARS Coronavirus Main Protease 3CLpro
Abstract
SARS (severe acute respiratory syndrome) is caused by a newly discovered coronavirus. A key enzyme for the maturation of this virus and, therefore, a target for drug development is the main protease 3CL(pro) (also termed SARS-CoV 3CL(pro)). We have cloned and expressed in Escherichia coli the full-length SARS-CoV 3CL(pro) as well as a truncated form containing only the catalytic domains. The recombinant proteins have been characterized enzymatically using a fluorescently labeled substrate; their structural stability in solution has been determined by differential scanning calorimetry, and novel inhibitors have been discovered. Expression of the catalytic region alone yields a protein with a reduced catalytic efficiency consistent with the proposed regulatory role of the alpha-helical domain. Differential scanning calorimetry indicates that the alpha-helical domain does not contribute to the structural stability of the catalytic domains. Analysis of the active site cavity reveals the presence of subsites that can be targeted with specific chemical functionalities. In particular, a cluster of serine residues (Ser139, Ser144, and Ser147) was identified near the active site cavity and was susceptible to being targeted by compounds containing boronic acid. This cluster is highly conserved in similar proteases from other coronaviruses, defining an attractive target for drug development. It was found that bifunctional aryl boronic acid compounds were particularly effective at inhibiting the protease, with inhibition constants as strong as 40 nM. Isothermal titration microcalorimetric experiments indicate that these inhibitors bind reversibly to 3CL(pro) in an enthalpically favorable fashion, implying that they establish strong interactions with the protease molecule, thus defining attractive molecular scaffolds for further optimization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., Zhao, Q., Zhou, Z., Pei, D., Ziebuhr, J., et al. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030324 · Cited by 727
Barretto, N., Jukneliene, D., Ratia, K., Chen, Z., Mesecar, A. D., & Baker, S. C. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15189-15198.2005 · Cited by 582
Small molecules targeting severe acute respiratory syndrome human coronavirus
Wu, C.-Y., Jan, J.-T., Ma, S.-H., Kuo, C.-J., Juan, H.-F., Cheng, Y.-S. E., Hsu, H.-H., Huang, H.-C., Wu, D., Brik, A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403596101 · Cited by 521
Boron Containing Compounds as Protease Inhibitors
Smoum, R., Rubinstein, A., Dembitsky, V. M., & Srebnik, M. (2012) · Chemical Reviews · doi:10.1021/cr608202m · Cited by 450
Goyal, B., & Goyal, D. (2020) · ACS Combinatorial Science · doi:10.1021/acscombsci.0c00058 · Cited by 344
Metadata
- Authors
- Bacha, U., Barrila, J., Velazquez-Campoy, A., Leavitt, S. A., & Freire, E.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2004-03-30
- Volume
- 43
- Issue
- 17
- Pages
- 4906-4912
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2039466442
- Cited by
- 218
- References
- 0
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of Novel Inhibitors of the SARS Coronavirus Main Protease 3CLpro. https://app.cochat.ai/papers/10.1021/bi0361766
- The paper
- Bacha, U., Barrila, J., Velazquez-Campoy, A., Leavitt, S. A., & Freire, E. (2004). Identification of Novel Inhibitors of the SARS Coronavirus Main Protease 3CLpro. Biochemistry. https://doi.org/10.1021/bi0361766
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.